全文获取类型
收费全文 | 189887篇 |
免费 | 17083篇 |
国内免费 | 8014篇 |
专业分类
耳鼻咽喉 | 2460篇 |
儿科学 | 4122篇 |
妇产科学 | 2277篇 |
基础医学 | 32443篇 |
口腔科学 | 5556篇 |
临床医学 | 14850篇 |
内科学 | 26321篇 |
皮肤病学 | 4640篇 |
神经病学 | 10497篇 |
特种医学 | 4654篇 |
外国民族医学 | 125篇 |
外科学 | 18063篇 |
综合类 | 30255篇 |
预防医学 | 4939篇 |
眼科学 | 5049篇 |
药学 | 15061篇 |
34篇 | |
中国医学 | 6374篇 |
肿瘤学 | 27264篇 |
出版年
2024年 | 65篇 |
2023年 | 2611篇 |
2022年 | 3497篇 |
2021年 | 5798篇 |
2020年 | 6104篇 |
2019年 | 5724篇 |
2018年 | 5942篇 |
2017年 | 6510篇 |
2016年 | 6530篇 |
2015年 | 7179篇 |
2014年 | 11293篇 |
2013年 | 12269篇 |
2012年 | 11104篇 |
2011年 | 12598篇 |
2010年 | 10537篇 |
2009年 | 10173篇 |
2008年 | 10695篇 |
2007年 | 10973篇 |
2006年 | 9834篇 |
2005年 | 8974篇 |
2004年 | 7901篇 |
2003年 | 6760篇 |
2002年 | 5548篇 |
2001年 | 4731篇 |
2000年 | 3851篇 |
1999年 | 3280篇 |
1998年 | 2671篇 |
1997年 | 2570篇 |
1996年 | 2223篇 |
1995年 | 2242篇 |
1994年 | 1978篇 |
1993年 | 1654篇 |
1992年 | 1351篇 |
1991年 | 1267篇 |
1990年 | 975篇 |
1989年 | 895篇 |
1988年 | 844篇 |
1987年 | 679篇 |
1986年 | 641篇 |
1985年 | 842篇 |
1984年 | 754篇 |
1983年 | 514篇 |
1982年 | 548篇 |
1981年 | 434篇 |
1980年 | 388篇 |
1979年 | 285篇 |
1978年 | 201篇 |
1977年 | 166篇 |
1976年 | 129篇 |
1975年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
肾脏是人体最重要的排泄器官。肾单元近端小管细胞具有多种药物转运体和代谢酶,在药物及其代谢物处置中发挥关键作用。近端小管细胞中主要转运体包括有机阴离子转运体、有机阳离子转运体、有机阳离子/肉毒碱转运体、多药及毒素外排转运蛋白、P-糖蛋白、乳腺癌耐药蛋白和多药耐药相关蛋白;主要代谢酶包括细胞色素P450酶,UDP-葡萄糖醛酸基转移酶、磺酸基转移酶、谷胱甘肽S-转移酶。肾脏转运体和/或代谢酶介导药物相互作用(DDIs)是临床关注的重要问题。肾脏转运体和代谢酶存在密切协作关系,在肾脏也存在多种相互作用现象(包括转运-转运相互作用,代谢-代谢相互作用和转运-代谢相互作用),其显著影响药物肾脏处置、临床疗效和肾毒性。本文系统阐述了这些相互作用对药物及其代谢物的肾脏排泄、药动学、DDIs和肾毒性的影响。今后需要进一步阐明肾脏转运-代谢相互作用机制,将有助于研究体内药物肾脏处置和DDIs,促进临床合理用药。 相似文献
2.
3.
4.
Since their inception in the 1960s–70s, mesenchymal stem/stromal cells (MSCs) have gained interest because of their differentiation potential, anti-inflammatory effects, and immune-modulating properties. Both cell-based and cell-free MSC treatments show healing capacity in injured tissues. Cell-based treatment comprises MSCs and all secreted products, whereas cell-free treatments include only the secreted products. MSCs are therapeutically administered to many damaged organs owing to their efficacy. Specifically, the eye is a unique organ system to study the effects of MSCs, as treatment is easily applied and measured owing to its external location. The eye holds an immune-privileged status, wherein inflammation and immune responses are innately down-regulated. As excessive inflammation in the cornea often leads to fibrosis and irreversible corneal hazing, many studies have investigated the anti-inflammatory and immune-modulating capacities of MSCs. Decades of research suggest that MSCs modulate the immune response by secreting cytokines, growth factors, and extracellular matrix proteins that inhibit the infiltration of inflammatory cells following injury and promote a healing phenotype via M2 macrophage polarization. MSCs have also shown trans-differentiation potential into cornea-specific cell types during the wound healing process, such as corneal epithelial, stromal, or endothelial cells. This review discusses recent investigations of MSC treatment in the cornea, focusing on therapeutic efficacy, mechanisms, and future directions. 相似文献
5.
6.
《Clinical lung cancer》2022,23(6):467-476
BackgroundImmune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been found to yield good outcomes. However, ICI monotherapy is still considered an important treatment option. Data on long-term progression-free survival (PFS) and OS in real-world settings are limited.Patients and MethodsThis was a multicenter retrospective observational study. A total of 435 consecutive patients histologically diagnosed with advanced, metastatic, or recurrent NSCLC treated with ICI monotherapy were enrolled in this study from December 2015 to December 2018. Clinical data were collected from electronic medical records and pharmacy databases.ResultsThe PFS and OS of the patients were 3.4 and 13.0 months, respectively. The objective response and disease control rates were 22.8% and 54.9%, respectively, and the 4-year survival rate was 17.9%. Multivariate analyses revealed that elder patients (>70 years), good Eastern Cooperative Oncology Group Performance Status (ECOG PS) score, programmed death-ligand 1 tumor proportion score (PD-L1 TPS) of ≥ 50%, absence of bone metastasis, and presence of immune-related skin toxicity, which is an immune-related adverse event, were correlated with good PFS. Moreover, good ECOG PS score, PD-L1 TPS of ≥ 50%, absence of bone metastasis, and presence of skin toxicity were correlated with good OS.ConclusionsThe 4-year survival rate was 17.9%. Good ECOG PS score, PD-L1 TPS of ≥ 50%, absence of bone metastasis, and presence of skin toxicity were correlated with good PFS and OS. 相似文献
7.
8.
《European journal of surgical oncology》2022,48(5):1062-1067
BackgroundSurgical resection is recommended for patients with resectable acinar cell carcinoma (ACC). The aim of this study was to investigate the clinical characteristics and surgical outcomes of resectable ACC in comparison to pancreatic ductal adenocarcinoma (PDAC).MethodA retrospective analysis was performed on all patients who consecutively underwent radical resection with pathologically confirmed ACC and PDAC from December 2011 to December 2018. Clinicopathologic characteristics and follow-up information were analyzed. A 1:3 propensity score matching (PSM) method was used to minimize the bias between ACC and PDAC.ResultsA total of 26 patients with ACC and 1351 with PDAC were included. Compared to PDAC, ACC tended to be larger (4.5 vs. 3.0 cm; p < 0.001) and more frequently located in the pancreatic body/tail (61.5% vs. 36.6%, p = 0.009), with lower total bilirubin levels, lower neutrophil lymphocyte ratio (NLR) levels and lower carbohydrate antigen 19-9 (CA19-9) levels and carcinoembryonic antigen (CEA) levels. There was no difference in postoperative morbidities in patients with ACC and PDAC. The median OS and RFS were longer in ACC when compared to PDAC (OS: 43.5 mo vs. 19.0 mo, p = 0.004; RFS: 24.5 mo vs. 11.6 mo, p = 0.023). After the 1:3 PSM, ACC remained to be a better histological type for OS (p = 0.024), but had comparable RFS with PDAC (p = 0.164).ConclusionPatients with ACC after radical resection had better OS than that with PDAC. However, ACC is also an aggressive tumor with a similar trend of RFS with PDAC after the matching, necessitating the multidisciplinary treatment for resectable ACC disease. 相似文献
9.
口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)的发病率和死亡率呈年轻化趋势上升,已成为世界范围内的主要公共卫生问题。近年来,慢性牙周炎(chronic periodontitis,CP)与口腔鳞癌之间的关系越来越受到重视,一些研究发现,以慢性炎症和微生物失调为特征的牙周病是口腔肿瘤发生的重要危险因素。本文就慢性牙周炎与口腔鳞癌的相关研究,牙周主要致病菌、细胞因子、NF-κB等在两者中的桥梁作用,以及抗炎药物在口腔鳞癌中的应用做主要阐述。 相似文献
10.